<p><strong> </strong><strong>In mCRPC patients without PSA progression or new symptoms, clinicians should perform imaging at least annually. (<em>Expert Opinion</em>)</strong></p>
Discussion
Discussion
<p>Response to treatment and/or disease progression among men with mCRPC may be evaluated through PSA testing, imaging, or change in disease-related symptoms. It is recommended that men with mCRPC undergo imaging at least annually owing to the fact that, in patients with mCRPC treated with enzalutamide prior to chemotherapy in the PREVAIL trial, radiographic progression occurred in 24.5% of patients without PSA progression. This suggests that routine imaging can identify a significant portion of patients with radiographic progression who would otherwise not be identified.<sup>108</sup> The precise timing of imaging among men with mCRPC should be determined by multiple factors including biochemical response to treatment, change in disease-related symptoms, and patient preference. Furthermore, clinicians should consider known differences in biochemical response to treatment among different therapies for mCRPC when determining the interval between imaging studies.</p>